 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
PhaseRx Inks Tech-Evaluation Deal with Monsanto as It Advances Liver Cancer Program
January 31, 2013
PhaseRx Inks Tech-Evaluation Deal with Monsanto as It Advances Liver Cancer Program
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Through Licensing Deal, Dow AgroSciences Gains Access to Monsanto RNAi Tech
April 25, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Max Planck, Isis, Monsanto, and More
March 14, 2013 / Gene Silencing News - Tekmira Provides Pipeline Update, Eyes Agricultural Market
February 14, 2013 / Gene Silencing News - Researchers Report on Use of RNAi to Combat Bee Parasite
January 31, 2013 / Gene Silencing News - Monsanto Moves Four RNAi Products through Pipeline, Posts Improved Fiscal First Quarter Financials
January 17, 2013 / Gene Silencing News